Open-label Randomized Controlled Trial Investigating the Effects of Peanut Protein Powder Supplement on Muscle Growth, Muscle Quality and Other Health Biomarkers in Older Adults Engaging in a Ten-week, Whole-body Resistance Training Program
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Aging
- Sponsor
- Auburn University
- Enrollment
- 41
- Locations
- 1
- Primary Endpoint
- Change in acute myofibrillar protein synthesis rates
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
This study will evaluate the adaptations in skeletal muscle that occur in response to 10 weeks of weight training with or without peanut protein supplementation in older adult men and women.
Detailed Description
Aging is associated with declines in muscle mass, physical strength and physical function. Adequate quality protein intake in aging adults is critical to preventing functional decline. Peanuts provide a unique blend of amino acids that can provide several health benefits to aging adults. While supplementing with peanut protein (PP) powder as part of a resistance training program may increase myofibrillar protein synthesis (i.e., the gold standard molecular assessment in deciphering a muscle-building response), and improve skeletal muscle quality and body composition, no study to date has made this determination. This is a two-phase study using both novel and conventional methods to assess how PP supplementation affects muscle tissue in older individuals who engage in resistance training. These two phases will be conducted as part of a 10-week randomized controlled trial in which men and women aged 50 years and older (n=60), will be stratified by gender and randomized to a resistance training intervention (whole body, two days per week) with PP powder (72g daily; n=15 males, n=15 females) provided during the intervention (immediate group, IG) or after the intervention (wait-list control, WLC, n=15 males, n=15 females). The aims of this study are to determine the acute (deuterium oxide tracer) and chronic (peripheral quantitative computed tomography) effects of PP during resistance training on skeletal muscle myofibrillar protein synthesis rates, changes in skeletal muscle size and quality, changes in whole and appendicular body composition (dual energy x-ray absorptiometry), changes in inflammatory markers and the fecal microbiome.
Investigators
Andrew Fruge
Assistant Professor
Auburn University
Eligibility Criteria
Inclusion Criteria
- •body mass index (body mass/height squared) less than 35 kg/m2
- •resting blood pressure averaging less than 140/90 mmHg (with or without medication)
Exclusion Criteria
- •known peanut allergy
- •actively participating in resistance training for more than 2 days/week
- •any known overt cardiovascular or metabolic disease
- •metal implants that will interfere with x-ray procedures
- •medically necessary radiation exposure in the last six months (except dental x-ray)
- •any medical condition that would contradict participating in an exercise program, giving blood or donating a skeletal muscle biopsy (i.e. blood clotting disorder or taking blood thinners)
Outcomes
Primary Outcomes
Change in acute myofibrillar protein synthesis rates
Time Frame: 24 hours
Change in right leg vastus lateralis myofibrillar protein synthesis rates using the integrated deuterium oxide technique from biopsies immediately before and 24 hours after resistance exercise
Change in mid-thigh skeletal muscle area and quality
Time Frame: 0-10 weeks
peripheral quantitative computed tomography (pQCT) cross-sectional image of mid-right thigh assessed for total muscle cross-sectional area, subcutaneous adipose tissue area, total intra- and inter-muscular adipose tissue area and overall muscle density
Secondary Outcomes
- Change in fecal microbiome composition(0-10 weeks)
- Change in whole-body and appendicular body composition(0-10 weeks)
- Change in Type I and II Muscle Fiber Cross-Sectional Area(0-10 weeks)
- Change in leg extensor isokinetic dynamometry(0-10 weeks)
- Change in inflammatory biomarkers(0-10 weeks)